Stockscreener 앱 받기
0.2411
2.16%
0.0051
시간 외 거래:
.25
0.0089
+3.69%
Plus Therapeutics Inc 주식(PSTV)의 최신 뉴스
PSTV Analyst Rating: D. Boral Capital Maintains Buy Rating | PST - GuruFocus
Plus Therapeutics Presents Analysis Showing CNSide May Reduce Leptomeningeal Metastases Costs by 40% - National Today
Plus Therapeutics (PSTV) Study Highlights Cost Benefits of Early LM Detection - GuruFocus
Plus Therapeutics Study Shows Early Detection Can Reduce Healthcare Costs - Intellectia AI
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40% - The Manila Times
Late-stage LM care can top $100,000 a month, Plus analysis says - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Plus Therapeutics (PSTV) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and Plus Therapeutics (PSTV) - The Globe and Mail
Plus Therapeutics Sets 2026 Virtual Annual Stockholder Meeting - The Globe and Mail
Plus: Q4 Earnings Snapshot - theheraldreview.com
Plus Therapeutics (PSTV) Beats EPS Expectations Despite Revenue Decline - GuruFocus
Plus Therapeutics (PSTV) Surpasses Q4 Revenue Expectations - GuruFocus
Plus Therapeutics Reports 2025 Results, Advances CNSide Commercial Rollout and REYOBIQ Clinical Program with 2026 Milestones - Minichart
PLUS THERAPEUTICS, INC. Files Form 8-K with SEC Detailing Shareholder Director Nomination Procedures and Company Information - Minichart
Plus Therapeutics, Inc. 2025 Annual Report: Precision Radiopharmaceuticals and CNS Cancer Innovations - Minichart
Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4 - Yahoo Finance
Plus: Q4 Financial Overview - Bitget
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ Clinical Program and CNSide Commercial Rollout - Bitget
Plus Therapeutics 2025 net loss widens - TradingView
[8-K] PLUS THERAPEUTICS, INC. Reports Material Event | PSTV SEC FilingForm 8-K - Stock Titan
Plus Therapeutics 10-K: $5.21M Grant Revenue, Net Loss $0.29 EPS - TradingView
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Plus Therapeutics (NASDAQ: PSTV) updates CNS oncology pipeline and CNSide - Stock Titan
Plus Therapeutics (PSTV) widens 2025 loss but strengthens cash and CNS programs - Stock Titan
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout - The Manila Times
Inside Plus Therapeutics' 2026 brain cancer drug and spinal fluid test plans - Stock Titan
PSTV Earnings History & Surprises | EPS & Revenue Results | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN
Can Plus Therapeutics Inc. stock deliver strong Q4 earningsEarnings Miss & Verified Short-Term Trading Plans - Naître et grandir
[RW] PLUS THERAPEUTICS, INC. SEC Filing - Stock Titan
PSTV SEC FilingsPlus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
138,897,548 Common Stock of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Certain Warrants of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Certain Restricted Stock Units of Plus Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-FEB-2026. - marketscreener.com
Lake Street Sticks to Their Buy Rating for Plus Therapeutics (PSTV) - The Globe and Mail
Plus Therapeutics (PSTV) CFO granted RSUs and stock options package - Stock Titan
PLUS Therapeutics (PSTV) CEO receives large RSU and stock option grants - Stock Titan
PLUS THERAPEUTICS, Inc.Common Stock (NQ: PSTV - The Chronicle-Journal
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ - Bitget
Plus Therapeutics, Inc. Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ - marketscreener.com
Plus Therapeutics (PSTV) Gains New CPT Code for Innovation in Br - GuruFocus
Plus Therapeutics announces new Category III CPT code - marketscreener.com
Plus Therapeutics Receives AMA Approval for New CPT Code for REYOBIQ in Treatment of CNS Cancers - Quiver Quantitative
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ - GlobeNewswire
PSTV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Value Recap: Is Plus Therapeutics Inc stock undervalued right nowWeekly Stock Summary & Short-Term Swing Trade Alerts - baoquankhu1.vn
Aug EndMonth: Is Plus Therapeutics Inc stock undervalued right nowMarket Weekly Review & Comprehensive Market Scan Reports - baoquankhu1.vn
Is Plus Therapeutics Inc. in accumulation or distribution phase2025 Retail Activity & Short-Term Trading Opportunity Alerts - mfd.ru
Plus Therapeutics Updates Executive Compensation, Approves 2025 Bonuses - The Globe and Mail
Aug Gainers: Can Plus Therapeutics Inc stock double in the next yearJuly 2025 Drop Watch & Stock Timing and Entry Methods - baoquankhu1.vn
Is Plus Therapeutics Inc. stock showing strong momentumGlobal Markets & Trade Opportunity Analysis - mfd.ru
Can Plus Therapeutics Inc. stock double in the next year2025 Retail Activity & Daily Market Momentum Tracking - mfd.ru
Aug Decliners: Can Plus Therapeutics Inc stock double in the next yearQuarterly Risk Review & Capital Efficient Trading Techniques - baoquankhu1.vn
Aug EndMonth: What is MPWRs valuation compared to sectorStock Surge & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV) - Yahoo Finance
Merger Talk: What is the dividend yield of Plus Therapeutics IncPortfolio Gains Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Market Rankings: Is Plus Therapeutics Inc stock undervalued right nowBond Market & Daily Entry Point Alerts - baoquankhu1.vn
Exit Recap: What is Atlas Lithium Corporations revenue forecastJuly 2025 Movers & AI Enhanced Execution Alerts - baoquankhu1.vn
Plus Therapeutics shares climb after subsidiary secures nationwide Humana coverage - MSN
1.20%
0.06%
자본화:
|
볼륨(24시간):